Last reviewed · How we verify
Inqovi
Inqovi is a Nucleoside Metabolic Inhibitor [EPC] Small molecule drug developed by Otsuka. It is currently FDA-approved (first approved 2020) for Chronic myelomonocytic leukemia, Myelodysplastic syndrome. Also known as: Decitabine, Cedazuridine, Decitabine and Cedazuridine, ASTX727.
Inqovi works by blocking the enzyme cytidine deaminase, allowing chemotherapy medications to be more effective.
Inqovi is a fixed-dose combination anticancer medication used for the treatment of adults with myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML). It is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor.
At a glance
| Generic name | Inqovi |
|---|---|
| Also known as | Decitabine, Cedazuridine, Decitabine and Cedazuridine, ASTX727, decitabine |
| Sponsor | Otsuka |
| Drug class | Nucleoside Metabolic Inhibitor [EPC] |
| Target | Cytidine deaminase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2020 |
Mechanism of action
Decitabine is nucleoside metabolic inhibitor that is believed to exert its effects after phosphorylation and direct incorporation into DNA and inhibition of DNA methyltransferase, causing hypomethylation of DNA and cellular differentiation and/or apoptosis. Decitabine inhibits DNA methylation in vitro, which is achieved at concentrations that do not cause major suppression of DNA synthesis. Decitabine-induced hypomethylation in cancer cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of decitabine may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine incorporated into DNA. Non-proliferating cells are relatively insensitive to decitabine.Cytidine deaminase (CDA) is an enzyme that catalyzes the degradation of cytidine, including the cytidine analog decitabine. High levels of CDA in the gastrointe
Approved indications
- Chronic myelomonocytic leukemia
- Myelodysplastic syndrome
Common side effects
- Fatigue
- Hemorrhage
- Edema
- Pyrexia
- Constipation
- Mucositis
- Nausea
- Diarrhea
- Transaminase increased
- Abdominal pain
- Vomiting
- Myalgia
Key clinical trials
- Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML (PHASE3)
- Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (PHASE1,PHASE2)
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
- A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) (PHASE2)
- Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia (PHASE1)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (PHASE1)
- Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inqovi CI brief — competitive landscape report
- Inqovi updates RSS · CI watch RSS
- Otsuka portfolio CI
Frequently asked questions about Inqovi
What is Inqovi?
How does Inqovi work?
What is Inqovi used for?
Who makes Inqovi?
Is Inqovi also known as anything else?
What drug class is Inqovi in?
When was Inqovi approved?
What development phase is Inqovi in?
What are the side effects of Inqovi?
What does Inqovi target?
Related
- Drug class: All Nucleoside Metabolic Inhibitor [EPC] drugs
- Target: All drugs targeting Cytidine deaminase
- Manufacturer: Otsuka — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Chronic myelomonocytic leukemia
- Indication: Drugs for Myelodysplastic syndrome
- Also known as: Decitabine, Cedazuridine, Decitabine and Cedazuridine, ASTX727, decitabine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing